We are excited to announce that one of the companies in our investment portfolio has successfully completed a new financing round. Genoa Pharmaceuticals, Inc., a privately held Seattle/San Diego-based pharmaceutical company developing next generation therapies for the treatment of Idiopathic Pulmonary Fibrosis, has raised $62 million in a Series A financing. The capital will be used to advance their lead asset, Aerodone™ for IPF through to Phase 2 proof-of-concept studies and will also support the development of additional assets within their pipeline towards clinical trials.

Aerodone™ is a unique reformulation of the FDA approved product Pirfenidone (Esbriet™) that is expected to improve its safety profile and enhance peripheral lung deposition in IPF patients, thereby increasing its efficacy.


If you wish to learn more about Genoa Pharmaceuticals, please visit their website: www.genoapharma.com

The InSymbiosis Team